Инкретиновата ос в кардиометаболитните заболявания – молекулярни и системни механизми на GLP-1 и GIP терапиите
Ключови думи :
инкретинова ос, GLP-1, GIP, кардиометаболитни заболявания, молекулярни механизмиАбстракт
Инкретиновата ос играе централна роля в регулацията на глюкозния метаболизъм и енергийния баланс, като нейната дисрегулация е ключов патофизиологичен механизъм при захарен диабет тип 2, затлъстяване и свързаните с тях кардиометаболитни заболявания. Глюкагон-подобният пептид-1 (GLP-1) и глюкозозависимият инсулинотропен полипептид (GIP) действат чрез рецепторно медиирани механизми, които засягат не само панкреасната функция, но и сърдечносъдовата система, мастната тъкан, черния дроб и централната нервна система. Съвременните терапевтични подходи, включващи GLP-1 рецепторни агонисти и dual incretin терапии, демонстрират широк спектър от ефекти, надхвърлящи гликемичния контрол. Настоящата обзорна статия има за цел да обобщи молекулярните и системните механизми на действие на тези терапии и тяхната роля в кардиометаболитните заболявания.
Литература (библиография)
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab, 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab, 2018;20(Suppl 1):5–21. doi:10.1111/dom.13129
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev, 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 2014;155(4):1280–1290. doi:10.1210/en.2013-1934
Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig, 2010;1(1-2):8–23. doi:10.1111/j.2040-1124.2010.00022.x
Erdogdu Ö, Nathanson D, Sjöholm Å, et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-dependent mechanisms. Cardiovasc Diabetol, 2010;9:54. doi:10.1186/1475-2840-9-54
Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Circulation, 2005;112(3):405–411. doi:10.1152/ajpheart.00347.2005
Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci, 2000;66(2):91–103. doi:10.1016/S0024-3205(99)00529-8
Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of GLP-1 but not of synthetic human GIP in patients with type-2 diabetes mellitus. J Clin Invest, 1993;91(1):301– 307. doi:10.1172/JCI116186
Finan B, Müller TD, Clemmensen C, et al. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med, 2016;22(5):359–376. doi:10.1016/j.molmed.2016.03.005
Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med, 2018;10(472):eaat3392. doi:10.1126/scitranslmed.aat3392
Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest, 2021;131(12):e146353. doi:10.1172/ JCI146353
Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus tractus solitarius project directly to the ventral tegmental area and nucleus accumbens to control feeding. Endocrinology, 2012;153(2):647–658. doi:10.1210/en.2011-1443
Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist-induced weight loss. J Clin Invest, 2014;124(10):4473–4488. doi:10.1172/JCI75276
Adriaenssens AE, Biggs EK, Darwish T, et al. Glucosedependent insulinotropic polypeptide receptor-expressing cells in the brain regulate energy homeostasis. Cell Metab, 2019;30(5):987–996. doi:10.1016/j.cmet.2019.07.011
Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol, 2016;78:277– 299. doi:10.1146/annurev-physiol-021115-105439
Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest, 2017;127(1):1–4. doi:10.1172/JCI92035
Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm, 2016;2016:3094642. doi:10.1155/2016/3094642
Ding X, Saxena NK, Lin S, et al. Exendin-4, a GLP-1 receptor agonist, improves hepatic steatosis and insulin sensitivity. Hepatology, 2006;43(1):173–181. doi:10.1002/hep.21006
Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab, 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation, 2007;115(10):1285–1295. doi:10.1161/CIRCULATIONAHA.106.652859
Nystrom T, Gutniak MK, Zhang Q, et al. Effects of GLP-1 on endothelial function in type 2 diabetes. Am J Physiol Endocrinol Metab, 2004;287(6):E1209–E1215. doi:10.1152/ajpendo.00211.2004
Ceriello A, Esposito K, Testa R, et al. The possible protective role of GLP-1 on endothelial dysfunction. Diabetologia, 2011;54(7):1781–1784. doi:10.1007/s00125-011-2159-1
Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting GLP- 1 analogue attenuates atherosclerosis in ApoE-/- mice. Diabetes, 2009;58(11):2712–2721. doi:10.2337/db09-0256
Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl peptidase-4 inhibition reduces atherosclerosis via antiinflammatory effects. Circulation, 2011;124(21):2338–2349. doi:10.1161/CIRCULATIONAHA.111.041418
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res, 2018;122(4):624–638. doi:10.1161/CIRCRESAHA.117.311586
Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes, 2005;54(1):146–151. doi:10.2337/diabetes.54.1.146
Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 in the heart. Cardiovasc Diabetol, 2008;7:10. doi:10.1186/1475-2840-7-10
Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail, 2006;12(9):694–699. doi:10.1016/j.cardfail.2006.08.211
Heimbürger SM, Bergmann NC, Augustin R, et al. Glucosedependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020;125:170174. doi:10.1016/j.peptides.2019.170174
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab, 2018;18:3–14. doi:10.1016/j. molmet.2018.09.009
Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes. Nat Med, 2015;21(1):27–36. doi:10.1038/nm.3761
Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab, 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med, 2021;385(6):503–515. doi:10.1056/ NEJMoa2107519
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet, 2021;398(10313):1811–1824. doi:10.1016/S0140-6736(21)02188-7
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med, 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet, 2019;394(10193):121–130. doi:10.1016/S0140- 6736(19)31149-3
Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in type 2 diabetes and obesity. Diabetes Ther, 2021;12(10):2505–2523. doi:10.1007/s13300-021-01115-4
Sattar N, McGuire DK. Pathways to cardiorenal benefits of GLP-1 receptor agonists. Nat Med, 2022;28(1):3–5. doi:10.1038/s41591-021-01640-3
Файлове за сваляне
Публикуван
Брой
Раздел (Секция)
Лиценз
Авторски права (c) 2026 D. Gospodinov, L. Hadzhiilieva, N. Gerasimov (Author)
Публикация с Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Можете свободно да споделяте, копирате и разпространявате материала във всякакъв носител или формат при следните условия.
